Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Mamma Screening

Between statistics and casuistry

    • Gynecology
    • News
    • Oncology
    • Prevention and health care
    • RX
  • 2 minute read

Once again, a health policy bombshell has burst in the Sunday press. The Swiss Medical Board questions systematic breast screening. As was to be expected, the tsunami of outrage arrived on Monday. Apparently, not all interested parties evaluate the same studies or interpret them differently.

What is the “number needed to screen” and the “number needed to hurt”? How many mammograms of what quality must be performed in how many women at what intervals to prevent a woman from dying from breast cancer? Does the interpretation and selection of studies depend on whether the experts’ primary goal is to reduce costs or to prevent as many women as possible from dying of breast cancer? How many women are unnecessarily confused by false positive results? In how many women is carcinoma missed despite the screening program? How many women may be made unnecessarily uncomfortable in order to provide relief to how many women? Is the pretest probability sufficiently high in the group of 50- to 69-year-old women? These questions can obviously be argued about!

The experts argue in public about an emotionally charged topic, and the layman wonders. On the Monday after the publication of the report at 09:00, the first patient already approaches me about the newspaper reports. She said she was upset and unsettled. She says her sister was diagnosed with breast cancer ten years ago at the age of 50 and to date has had no recurrence. Two years ago, she, my now 69-year-old patient, had her annual checkup with a new gynecologist. She had a guilty conscience because she had not had a mammogram for two years. It had been drilled into her that she needed to have annual mammograms. The visit to the gynecologist was very disappointing. The examination had been limited to taking the cancer smear. She had not had to remove her blouse and her breasts had not been examined. For this, she was registered at the hospital for a mammogram. Until today, she had not been under control and she would be grateful if I would recommend another doctor to her.

The public campaigns, discussions and policies cannot do justice to the individual woman. They promote uncertainty. Thus, one woman is afraid of missing a tumor, another of being unnecessarily upset and needlessly made ill.

You, dear colleagues, have the task of advising each individual woman, examining her carefully and taking the measures that meet her needs. You cannot escape this responsibility, now even more so when the experts are arguing.

Cordially, your

Josef Widler, MD

HAUSARZT PRAXIS 2014; 9(2): 1

Publikation
  • HAUSARZT PRAXIS
Related Topics
  • Breast Cancer
  • Carcinoma
  • Costs
  • gynecologist
  • gynecologist
  • Mamma Screening
  • mammography
  • Recurrence
  • swiss medical board
Previous Article
  • Successful therapy of pAVD with EGb 761®.

Clinical studies document the efficacy of Ginkgo biloba extract

  • Angiology
  • Cardiology
  • News
  • RX
View Post
Next Article
  • Diabetes mellitus

First Google medical product in development

  • Endocrinology and Diabetology
  • News
  • Prevention and health care
  • RX
View Post
You May Also Like
View Post
  • 8 min
  • Proteins in wound healing

Do special amino acids lead to success?

    • CME continuing education
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • RX
    • Studies
View Post
  • 4 min
  • HER2+ early breast cancer

DESTINY-Breast11 – neoadjuvant T-DXd without anthracyclines

    • Education
    • Gynecology
    • Oncology
    • RX
    • Studies
View Post
  • 3 min
  • Lavender aromatherapy

Take away the fear of the dentist

    • Dentistry
    • Education
    • Pharmaceutical medicine
    • Phytotherapy
    • Psychiatry and psychotherapy
    • RX
    • Studies
View Post
  • 4 min
  • Digital dermatology: innovative project examples

AI and eHealth tools in HS care

    • Dermatology and venereology
    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
    • Studies
View Post
  • 5 min
  • Mantle cell lymphoma

Recurrence after BTK inhibition – prognostic factors and treatment options

    • Education
    • Hematology
    • Oncology
    • RX
View Post
  • 3 min
  • Dementia risk with type 2 diabetes

SGLT2 inhibitors with advantages vs. DPP4 inhibitors

    • Education
    • Endocrinology and Diabetology
    • Geriatrics
    • Neurology
    • Pharmacology and toxicology
    • Psychiatry and psychotherapy
    • RX
    • Studies
View Post
  • 15 min
  • T helper 1 cells

Differentiation and activation of Th1 cells – a multi-omics approach

    • RX
    • CME continuing education
    • General Internal Medicine
    • Genetics
    • Prevention and health care
View Post
  • 4 min
  • Cannabis for schizophrenia

CBD pre-treatment could exacerbate side effects

    • Education
    • Pharmacology and toxicology
    • Phytotherapy
    • Psychiatry and psychotherapy
    • RX
    • Studies
  • IBD matters

    Zum Thema
Top CME content
  • 1
    Communication as the key to therapy adherence
  • 2
    Solutions to the malnutrition dilemma
  • 3
    Solutions to the malnutrition dilemma
  • 4
    Focus on preventive care options
  • 5
    Fertility preservation from gonads to genomes to genoids

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.